![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa announces commencement of re-dosing of drisapersen in North America in patients with Duchenne muscular dystrophy
17 sept. 2014 14h52 HE
|
Prosensa Holding N.V.
Leiden, The Netherlands, Sept. 17, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high unmet...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa announces 12 presentations at the 19th International Congress of the World Muscle Society in Berlin
09 sept. 2014 09h00 HE
|
Prosensa Holding N.V.
LEIDEN, The Netherlands, Sept. 9, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high unmet...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa announces Lancet Neurology publication of an exploratory phase II study (DEMAND II) demonstrating efficacy and safety of drisapersen in patients with Duchenne muscular dystrophy
08 sept. 2014 08h00 HE
|
Prosensa Holding N.V.
Leiden, The Netherlands, Sept. 8, 2014 (GLOBE NEWSWIRE) -- LEIDEN, The Netherlands - September 8,
2014 - Prosensa Holding N.V. (NASDAQ: RNA), the
biopharmaceutical company focusing on RNA-modulating...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa to Present at Upcoming Conferences
03 sept. 2014 08h51 HE
|
Prosensa Holding N.V.
Leiden, The Netherlands, Sept. 3, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today announced
presentations at upcoming investor conferences. Celia Economides,
Senior Director,...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Announces 2nd Quarter 2014 Financial Results and Recent Corporate Developments
12 août 2014 07h00 HE
|
Prosensa Holding N.V.
NDA submission for drisapersen in Q4 2014 on track
EMA filing for conditional approval following NDA Submission
Drisapersen re-dosing on track prior to the end of September
Cash &...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa and CureDuchenne Strengthen Long-term Collaboration with an Additional [Eur]5M to Advance DMD Pipeline
11 août 2014 16h00 HE
|
Prosensa Holding N.V.
Leiden, The Netherlands, Aug. 11, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high unmet...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa to Present at the Wedbush 2014 Life Sciences Conference
06 août 2014 08h00 HE
|
Prosensa Holding N.V.
Leiden, The Netherlands, Aug. 6, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today announced that Hans
Schikan, Chief Executive Officer, will present a corporate overview
at the...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Holding N.V. to Webcast Conference Call Discussing 2nd Quarter 2014 Financial Results and Corporate Update on August 12, 2014
04 août 2014 08h00 HE
|
Prosensa Holding N.V.
Leiden, The Netherlands, Aug. 4, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today
announced that the Company will host a conference call and live
audio webcast on Tuesday,...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Announces Extraordinary Shareholder Meeting to Appoint Dr. Annalisa Jenkins
14 juil. 2014 08h00 HE
|
Prosensa Holding N.V.
Leiden, The Netherlands, July 14, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical
company focusing on rare diseases with a high unmet medical need,
today...
![Prosensa Holding B.V. Logo](/news-release/logo/260297/0/260297.jpg?lastModified=12%2F09%2F2016%2022%3A37%3A21&size=2)
Prosensa Files F-3 SEC Mixed Shelf Registration For Up To $150 Million
07 juil. 2014 13h58 HE
|
Prosensa Holding N.V.
Leiden, The Netherlands, July 7, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) the Dutch biopharmaceutical
company focusing on rare diseases with a high unmet medical need,
today...